Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.Â
TUTIVIA
Tutivia™ is a blood-based proactive risk assessment tool for acute rejection in your kidney transplant patients. Tutivia™ uses RNA sequencing technology that helps answer your questions to deliver a more patient-centric care plan.
CLARAVA
Clarava™ utilizes an RNA gene signature to help define individual patient risk for acute rejection, during the pre-transplant assessment of a patient listed for kidney transplant. This can help clinicians accurately determine the level of immunosuppression in a more personalized manner.
PROTEGA
Protega™ will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. This can help clinicians determine the appropriate treatment to delay or reduce progressive fibrosis.
